Prostate Cancer Foundation Issues $4.5 Million in Grants to Support Innovation from Young Investigators
News Apr 22, 2010
The Prostate Cancer Foundation (PCF) has announced the funding of 21 new Young Investigator Awards at 17 leading cancer centers in the U.S. and Canada. Designed to encourage the innovative minds in cancer research to focus their careers on prostate cancer, the awards provide recipients with three years of funding to test transformational research questions for prostate cancer patients.
The 2010 Young Investigator Awards represent a new $4.5 million investment in the global cancer research community by PCF.
With the announcement of the 2010 Young Investigators, PCF is now funding 43 research projects led by young investigators around the world. These Young Investigator projects are three years in duration. Each award is $225,000 total and is matched dollar for dollar or matched in kind by the recipients’ research institutions, making the total award worth $450,000 in support.
“We are investing in the careers of the world’s ‘best of the best’ in computer science, molecular biology, pharmacology, radiation oncology, medical oncology and endocrinology to answer the challenge of discovering better treatments and cures for prostate cancer,” commented Howard R. Soule, PhD, executive vice president and chief science officer for PCF.
“The research mentors of these Young Investigators are as expert, accomplished and committed as we have ever seen,” said Jonathan W. Simons, MD, president and CEO of PCF. “We look forward to seeing the contributions these young scientists will make in our field.”
When the Human Genome Project was completed, in 2003, it opened the door to a radical new idea of health - that of personalized medicine, in which disease risk and appropriate treatment would be gleaned from one's genetic makeup. In a new article, researchers discuss how gene interaction networks hold the clues to disease susceptibility and treatment response.READ MORE
Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative diseases in human brain tissue samples, including Alzheimer’s disease and chronic traumatic encephalopathy. Their discovery will help scientists develop targeted biomarkers and therapeutics, resulting in a more accurate diagnosis of complex brain diseases.READ MORE